European urology oncology最新文献

筛选
英文 中文
Stereotactic Radiation for Primary Renal Cell Carcinoma: Is It Ready for Prime Time? 立体定向放射治疗原发性肾细胞癌:准备好了吗?
IF 8.3 1区 医学
European urology oncology Pub Date : 2025-03-14 DOI: 10.1016/j.euo.2025.02.014
Raquibul Hannan , Veronica Mollica , Carlotta Palumbo , Selcuk Erdem
{"title":"Stereotactic Radiation for Primary Renal Cell Carcinoma: Is It Ready for Prime Time?","authors":"Raquibul Hannan , Veronica Mollica , Carlotta Palumbo , Selcuk Erdem","doi":"10.1016/j.euo.2025.02.014","DOIUrl":"10.1016/j.euo.2025.02.014","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"8 3","pages":"Pages 597-600"},"PeriodicalIF":8.3,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Active Surveillance of Grade Group 2 Prostate Cancer: Oncological Outcomes from a Contemporary European Cohort. 2级前列腺癌的主动监测:来自当代欧洲队列的肿瘤预后。
IF 8.3 1区 医学
European urology oncology Pub Date : 2025-02-17 DOI: 10.1016/j.euo.2025.01.009
Michael Baboudjian, Riccardo Leni, Marco Oderda, Arthur Peyrottes, Claudia Kesch, Mulham Al-Nader, Alessandro Uleri, Charles Dariane, Helene Baud, Jonathan Olivier, Anna Redondo Rios, Francesco Sanguedolce, Vincent Benard, Olivier Windisch, Massimo Valerio, Giorgio Gandaglia, Guillaume Ploussard
{"title":"Active Surveillance of Grade Group 2 Prostate Cancer: Oncological Outcomes from a Contemporary European Cohort.","authors":"Michael Baboudjian, Riccardo Leni, Marco Oderda, Arthur Peyrottes, Claudia Kesch, Mulham Al-Nader, Alessandro Uleri, Charles Dariane, Helene Baud, Jonathan Olivier, Anna Redondo Rios, Francesco Sanguedolce, Vincent Benard, Olivier Windisch, Massimo Valerio, Giorgio Gandaglia, Guillaume Ploussard","doi":"10.1016/j.euo.2025.01.009","DOIUrl":"https://doi.org/10.1016/j.euo.2025.01.009","url":null,"abstract":"<p><strong>Background and objective: </strong>Uptake of active surveillance for patients with Gleason grade group (GG) 2 prostate cancer (PCa) remains low. Magnetic resonance imaging (MRI) before biopsy would allow better patient selection, but there are no published data on this strategy. Our aim was to report one of the first European AS series of patients with GG 2 PCa selected via MRI before image-guided biopsy.</p><p><strong>Methods: </strong>This multicenter study enrolled patients with GG 2 PCa managed with AS between 2016 and 2024 in ten reference centers in France, Spain, Italy, Switzerland, and Germany. Patients deemed unsuitable for curative treatment (ie, watchful waiting) were excluded. The primary endpoint was metastasis-free survival.</p><p><strong>Key findings and limitations: </strong>A total of 139 patients with GG 2 PCa were included. Baseline MRI revealed a lesion with a Prostate Imaging-Reporting and Data System score of 4-5 in 81 patients (59%). Median event-free follow-up was 38 mo (interquartile range 20-63). Two cases of metastasis were observed, and there were no deaths due to PCa. The estimated 3-yr metastasis-free survival rate was 98.1% (95% confidence interval 95.5-100%). Overall, 56 patients underwent definitive treatment and 26 were reclassified as having GG 3 PCa during follow-up. Among the 28 patients who underwent radical prostatectomy, final pathology revealed adverse features (GG 3 and/or pT3a) in 13 cases (46%), but very aggressive disease (GG ≥4 and/or ≥pT3b and/or pN1) was noted in only two cases (7%). There were no statistically significant differences in outcomes between groups that did and did not meet the European Association of Urology inclusion criteria for AS (all log-rank tests p > 0.05).</p><p><strong>Conclusions and clinical implications: </strong>In the era of prebiopsy MRI and image-guided biopsy, AS is a safe management option for selected patients with GG 2 PCa. Future studies should focus on redefining current inclusion criteria for AS in the targeted biopsy era, as many patients with GG 2 PCa are at low absolute risk of distant progression.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Are Patients with Prostate Imaging Reporting and Data System 5 Lesions Eligible for Active Surveillance? A Multicentric European Study. 前列腺影像学报告和数据系统5病变的患者是否有资格接受主动监测?一个多中心的欧洲研究。
IF 8.3 1区 医学
European urology oncology Pub Date : 2025-02-17 DOI: 10.1016/j.euo.2025.01.008
Arthur Peyrottes, Michael Baboudjian, Romain Diamand, Quentin Ducrot, Cyril Vitard, Arthur Baudewyns, Olivier Windisch, Julien Anract, Charles Dariane, Thibault Tricard, Julien Sarkis, Yvanne Sadreux, Marco Oderda, Thibaut Long Depaquit, Alexandre De La Taille, Jonathan Olivier, Laurent Brureau, Olivier Rouviere, Sébastien Crouzet, Alain Ruffion, François Desgrandchamps, Matthieu Roumiguie, Morgan Rouprêt, Guillaume Ploussard, Gaelle Fiard
{"title":"Are Patients with Prostate Imaging Reporting and Data System 5 Lesions Eligible for Active Surveillance? A Multicentric European Study.","authors":"Arthur Peyrottes, Michael Baboudjian, Romain Diamand, Quentin Ducrot, Cyril Vitard, Arthur Baudewyns, Olivier Windisch, Julien Anract, Charles Dariane, Thibault Tricard, Julien Sarkis, Yvanne Sadreux, Marco Oderda, Thibaut Long Depaquit, Alexandre De La Taille, Jonathan Olivier, Laurent Brureau, Olivier Rouviere, Sébastien Crouzet, Alain Ruffion, François Desgrandchamps, Matthieu Roumiguie, Morgan Rouprêt, Guillaume Ploussard, Gaelle Fiard","doi":"10.1016/j.euo.2025.01.008","DOIUrl":"https://doi.org/10.1016/j.euo.2025.01.008","url":null,"abstract":"<p><strong>Background and objective: </strong>Patients with Prostate Imaging Reporting and Data System (PI-RADS) 5 lesions are at a high risk of clinically significant prostate cancer (PCa), extracapsular extension, and biochemical recurrence (BCR) after local treatment. Managing these patients with active surveillance (AS) can be particularly challenging when targeted biopsies indicate favorable-risk tumors. This study aims to evaluate the outcomes of patients with PI-RADS 5 lesions managed with AS.</p><p><strong>Methods: </strong>We analyzed data from 126 patients treated at 16 centers in France, Italy, Switzerland, and Belgium, whose initial magnetic resonance imaging revealed at least one PI-RADS 5 lesion and who subsequently underwent AS. The primary endpoint was BCR-free survival. The secondary endpoints included metastasis-free survival, time to biopsy grade reclassification, and time to AS discontinuation, along with their predictors.</p><p><strong>Key findings and limitations: </strong>After a median follow-up of 36 mo after confirmatory biopsies (95% confidence interval [CI] 23-55), BCR was observed in five patients, with the median time not reached. The 5-yr BCR-free survival rate was 88% (95% CI 79-99%). No metastatic progression was reported. Seventeen patients experienced biopsy grade reclassification (median time not reached), and 55 patients discontinued AS. The median time to AS discontinuation was 55 mo (95% CI 46 mo-not applicable). The 5-yr AS discontinuation-free survival rate was 41% (95% CI 30.8-54.6%). On a multivariate Cox regression analysis, baseline prostate-specific antigen density and the percentage of positive biopsy cores were associated with biopsy grade reclassification, AS discontinuation, and BCR.</p><p><strong>Conclusions and clinical implications: </strong>With strict monitoring, AS is a safe management option for patients with PI-RADS 5 lesions and favorable-risk PCa. Limitations are mainly inherent to the retrospective design of this study.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative Performance of Machine Learning Models in Reducing Unnecessary Targeted Prostate Biopsies. 机器学习模型在减少不必要的前列腺活检中的比较性能。
IF 8.3 1区 医学
European urology oncology Pub Date : 2025-02-08 DOI: 10.1016/j.euo.2025.01.005
Fuyao Chen, Roxana Esmaili, Ghazal Khajir, Tal Zeevi, Moritz Gross, Michael Leapman, Preston Sprenkle, Amy C Justice, Sandeep Arora, Jeffrey C Weinreb, Michael Spektor, Steffan Huber, Peter A Humphrey, Angelique Levi, Lawrence H Staib, Rajesh Venkataraman, Darryl T Martin, John A Onofrey
{"title":"Comparative Performance of Machine Learning Models in Reducing Unnecessary Targeted Prostate Biopsies.","authors":"Fuyao Chen, Roxana Esmaili, Ghazal Khajir, Tal Zeevi, Moritz Gross, Michael Leapman, Preston Sprenkle, Amy C Justice, Sandeep Arora, Jeffrey C Weinreb, Michael Spektor, Steffan Huber, Peter A Humphrey, Angelique Levi, Lawrence H Staib, Rajesh Venkataraman, Darryl T Martin, John A Onofrey","doi":"10.1016/j.euo.2025.01.005","DOIUrl":"https://doi.org/10.1016/j.euo.2025.01.005","url":null,"abstract":"<p><strong>Background and objective: </strong>Conventional core needle biopsy for prostate cancer diagnosis can lead to diagnostic uncertainty and complications, prompting exploration of alternative risk assessment approaches that use clinical and imaging features. Our aim was to evaluate the effectiveness of machine learning (ML) models in reducing unnecessary biopsies.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of data for 1884 patients across two academic centers who underwent prostate magnetic resonance imaging and biopsy between 2016 and 2020 or 2004 and 2011. Twelve ML models were assessed for prediction of clinically significant prostate cancer (csPCa; Gleason grade group ≥2) using combinations of clinical features, including patient age, prostate-specific antigen level and density, Prostate Imaging-Reporting and Data System/Likert score, lesion volume, and gland volume. The models were trained and validated using a tenfold split for intrasite, intersite, and combined-site data sets. Model effectiveness was evaluated using the area under the receiver operating characteristic curve and decision curve analysis.</p><p><strong>Key findings and limitations: </strong>The best-performing ML model would reduce the number of biopsies by 13.07% at a false-negative rate of 1.91%. Performance was consistent across sites, although the study is limited by the small number of centers and the absence of specific clinical data.</p><p><strong>Conclusions and clinical implications: </strong>ML-enhanced clinical models provide an effective and generalizable approach for prediction of csPCa using standard clinical data. These models allow personalized risk assessment and follow-up, support clinical decision-making, and improve workflow efficiency.</p><p><strong>Patient summary: </strong>Models that are enhanced by machine learning can predict the severity of prostate cancer and help doctors in tailoring treatments for individual patients. This approach can simplify health care decisions and improve clinical efficiency.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Towards a Consensus on the Management of Metastatic Renal Cell Carcinoma: Insights from a European Delphi Study. 对转移性肾细胞癌管理的共识:来自欧洲德尔菲研究的见解。
IF 8.3 1区 医学
European urology oncology Pub Date : 2025-02-08 DOI: 10.1016/j.euo.2025.01.007
Laurence Albiges, Marine Gross-Goupil, Philippe Barthélémy, Aristotelis Bamias, Jens Bedke, Axel Bex, Mário Fontes-Sousa, Viktor Grünwald, Bohuslav Melichar, Lisa Pickering, Camillo Porta, Giuseppe Procopio, Sylvie Rottey, Manuela Schmidinger, Cristina Suárez, Guillermo Velasco, Bernard Escudier
{"title":"Towards a Consensus on the Management of Metastatic Renal Cell Carcinoma: Insights from a European Delphi Study.","authors":"Laurence Albiges, Marine Gross-Goupil, Philippe Barthélémy, Aristotelis Bamias, Jens Bedke, Axel Bex, Mário Fontes-Sousa, Viktor Grünwald, Bohuslav Melichar, Lisa Pickering, Camillo Porta, Giuseppe Procopio, Sylvie Rottey, Manuela Schmidinger, Cristina Suárez, Guillermo Velasco, Bernard Escudier","doi":"10.1016/j.euo.2025.01.007","DOIUrl":"https://doi.org/10.1016/j.euo.2025.01.007","url":null,"abstract":"<p><strong>Background and objective: </strong>Management of metastatic renal cell carcinoma (mRCC) remains complex despite clinical guidelines. The aim of this Delphi study was to achieve consensus among RCC experts on the definition, diagnosis, and first-line treatments for mRCC.</p><p><strong>Methods: </strong>Between May 2023 and April 2024, 14 experts from ten European countries completed two Delphi rounds of a 51-item questionnaire covering four topics: (1) oligometastatic RCC; (2) first-line treatment for metastatic clear-cell RCC; (3) treatment duration for metastatic clear-cell RCC; and (4) treatment of non-clear-cell RCC. Agreement was scored as absent/poor (<50%), fair (50-74%), or consensus (≥75%).</p><p><strong>Key findings and limitations: </strong>Consensus was reached for 12 of 51 items (24%) in the first round and 25 of 49 items (51%) by the study end. Notably, 79% of experts defined oligometastatic RCC as five or fewer metastases and agreed that it typically does not require immediate systemic treatment. All experts (100%) emphasized the importance of clinical performance status in guiding treatment for metastatic clear-cell RCC, with 86% agreeing on additional factors such as International Society of Urological Pathology grade and sarcomatoid features. Nivolumab plus cabozantinib was favored for patients with brain or bone metastases (93% and 86% agreement, respectively), while there was fair agreement on pembrolizumab plus lenvatinib for patients with liver metastases. In addition, 71% supported stopping immune checkpoint inhibitors after 2 yr, while 86% agreed on the undefined duration of tyrosine kinase inhibitor therapy.</p><p><strong>Conclusions and clinical implications: </strong>This Delphi study offers insights into mRCC management, and highlights the importance of multidisciplinary discussions for this challenging disease.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Results of Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma in a Large Multicenter Series 立体定向体放射治疗原发性肾细胞癌的大型多中心系列研究结果。
IF 8.3 1区 医学
European urology oncology Pub Date : 2025-02-07 DOI: 10.1016/j.euo.2025.01.001
Ludwige Abancourt , Muhammad Ali , Magali Quivrin , Jennifer Wallet , Ulrike Schick , Gianluca Ingrosso , Stéphane Supiot , Ciro Franzese , Marta Scorsetti , Linda Kerkmeijer , Andrei Fodor , Nadia Di Muzio , Natacha Jousset , Thomas Boisserie , Beatrice Detti , Luca Nicosia , Filippo Alongi , Fabio Trippa , Thomas Leleu , Loïsse Dessoude , David Pasquier
{"title":"Results of Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma in a Large Multicenter Series","authors":"Ludwige Abancourt ,&nbsp;Muhammad Ali ,&nbsp;Magali Quivrin ,&nbsp;Jennifer Wallet ,&nbsp;Ulrike Schick ,&nbsp;Gianluca Ingrosso ,&nbsp;Stéphane Supiot ,&nbsp;Ciro Franzese ,&nbsp;Marta Scorsetti ,&nbsp;Linda Kerkmeijer ,&nbsp;Andrei Fodor ,&nbsp;Nadia Di Muzio ,&nbsp;Natacha Jousset ,&nbsp;Thomas Boisserie ,&nbsp;Beatrice Detti ,&nbsp;Luca Nicosia ,&nbsp;Filippo Alongi ,&nbsp;Fabio Trippa ,&nbsp;Thomas Leleu ,&nbsp;Loïsse Dessoude ,&nbsp;David Pasquier","doi":"10.1016/j.euo.2025.01.001","DOIUrl":"10.1016/j.euo.2025.01.001","url":null,"abstract":"<div><h3>Background and objective</h3><div>For inoperable patients, stereotactic body radiation therapy (SBRT) is a noninvasive treatment approach for primary renal cell carcinoma (RCC). We aimed to evaluate local control (LC) of primary RCC treated with SBRT.</div></div><div><h3>Methods</h3><div>This multicenter retrospective study involved 16 centers in Australia, France, Italy, and the Netherlands. The primary endpoint was the LC probability, and the secondary endpoints were progression-free survival, overall survival (OS), cumulative incidence of cancer-related deaths, toxicities, and renal function evolution after SBRT.</div></div><div><h3>Key findings and limitations</h3><div>A total of 144 patients, treated between 2008 and 2020, with a median follow-up of 43 mo (interquartile range [IQR], 24.0–81.2), were included. The median age was 76 yr (IQR, 67.0–82.0) and the median tumor size was 4.4 cm (IQR, 3.3–5.6). The median baseline estimated glomerular filtration rate (eGFR) was 60 ml/min/1.73 m<sup>2</sup>. Of the patients, 40% had mild to moderate eGFR (30–60 ml/min). The two main treatment regimens were 42 Gy in three fractions and 26 Gy in one fraction. The LC probability was 98% at 1 yr (95% confidence interval [CI], 94–99) and 96% (95% CI, 92–99) at 5 yr. The median OS was 58 mo and the cumulative incidence of cancer-related deaths was 8% (95% CI, 3–15) at 5 yr. Seventy-one patients (49%) experienced at least one toxicity, including grade 1 in the majority (32%), grade 2 (14%), and grade 3 (1%). Two patients (1%) underwent dialysis (grade 4). The median eGFR loss was –7 ml/min (IQR, –17; 0) at the last follow-up.</div></div><div><h3>Conclusions and clinical implications</h3><div>This large series of primary RCC treated with SBRT demonstrates excellent LC and renal function preservation, and is associated with an acceptable toxicity profile. SBRT is an alternative treatment for inoperable patients.</div></div>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"8 3","pages":"Pages 774-781"},"PeriodicalIF":8.3,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051–60 回复:Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer等。口服达罗卢胺单药治疗与雄激素剥夺治疗在男性激素敏感前列腺癌中的2期随机开放标签研究(EORTC-GUCG 1532)欧洲石油学报,2024;7:1051-60。
IF 8.3 1区 医学
European urology oncology Pub Date : 2025-02-07 DOI: 10.1016/j.euo.2025.01.012
Francesco Montorsi , Giorgio Gandaglia , Francesco Barletta , Alberto Briganti
{"title":"Re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051–60","authors":"Francesco Montorsi ,&nbsp;Giorgio Gandaglia ,&nbsp;Francesco Barletta ,&nbsp;Alberto Briganti","doi":"10.1016/j.euo.2025.01.012","DOIUrl":"10.1016/j.euo.2025.01.012","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"8 3","pages":"Page 856"},"PeriodicalIF":8.3,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes. PARP抑制剂暴露与去势抵抗前列腺癌患者177Lu-PSMA-617术后临床结果的关系及DNA同源重组修复基因突变
IF 8.3 1区 医学
European urology oncology Pub Date : 2025-02-06 DOI: 10.1016/j.euo.2025.01.002
Ruben Raychaudhuri, Abuzar Moradi Tuchayi, Soon Khai Low, Ali T Arafa, Laura S Graham, Roman Gulati, Colin C Pritchard, Robert B Montgomery, Michael C Haffner, Peter S Nelson, Evan Y Yu, Jessica E Hawley, Heather H Cheng, George Mo, Delphine L Chen, Emmanuel S Antonarakis, Deepak Kilari, Thomas A Hope, Amir Iravani, Michael T Schweizer
{"title":"Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after <sup>177</sup>Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes.","authors":"Ruben Raychaudhuri, Abuzar Moradi Tuchayi, Soon Khai Low, Ali T Arafa, Laura S Graham, Roman Gulati, Colin C Pritchard, Robert B Montgomery, Michael C Haffner, Peter S Nelson, Evan Y Yu, Jessica E Hawley, Heather H Cheng, George Mo, Delphine L Chen, Emmanuel S Antonarakis, Deepak Kilari, Thomas A Hope, Amir Iravani, Michael T Schweizer","doi":"10.1016/j.euo.2025.01.002","DOIUrl":"10.1016/j.euo.2025.01.002","url":null,"abstract":"<p><strong>Background and objective: </strong>The prostate-specific membrane antigen (PSMA) radioligand <sup>177</sup>Lu-PSMA-617 (LuPSMA) is approved for treatment of metastatic castration-resistant prostate cancer (mCRPC). PARP inhibitors (PARPi) are approved for patients with mCRPC and mutations in homologous recombination repair (HRR) pathway genes. Both modalities induce DNA damage and therefore may share mechanisms of resistance. We investigated whether PARPi exposure would reduce the subsequent efficacy of LuPSMA.</p><p><strong>Methods: </strong>This retrospective study included 100 patients with a PARPi-qualifying HRR alteration treated with LuPSMA. Clinical outcomes on LuPSMA, including PSA<sub>50</sub> response, PSA progression-free survival (PFS), and overall survival (OS), were compared between those who had not previously received PARPi (PARPi-N) and those who had (PARPi-T). Subgroup analyses were performed for the most frequent HRR alterations (BRCA2 and ATM).</p><p><strong>Key findings and limitations: </strong>PSA<sub>50</sub> responses on LuPSMA were similar between PARPi-N (n = 47) and PARPi-T (n = 53), although PSA PFS was longer in the PARPi-N group (9.1 vs 4.8 mo; p = 0.037). Among patients with BRCA2 alterations, the PARPi-N group had a better PSA<sub>50</sub> response rate (89% vs 35%; p = 0.009), PSA PFS (14 vs 2.9 mo; p = 0.026), and OS (19 vs 5.3 mo; p = 0.10). PARPi exposure did not influence LuPSMA outcomes among patients with ATM alterations. Limitations include the retrospective design and differences in prior lines of therapy between the groups.</p><p><strong>Conclusions and clinical implications: </strong>PARPi exposure is associated with inferior LuPSMA outcomes, particularly for patients with BRCA2 alterations. These findings suggest potential cross-resistance and underscore the need for prospective studies assessing the optimal sequencing of these agents.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti’s Letter to the Editor re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051–60 回复Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta和Alberto Briganti给编辑的信:Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer等。口服达罗卢胺单药治疗与雄激素剥夺治疗在男性激素敏感前列腺癌中的2期随机开放标签研究(EORTC-GUCG 1532)欧洲石油学报,2024;7:1051-60。
IF 8.3 1区 医学
European urology oncology Pub Date : 2025-02-05 DOI: 10.1016/j.euo.2025.01.010
Bertrand Tombal , Yohann Loriot
{"title":"Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti’s Letter to the Editor re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051–60","authors":"Bertrand Tombal ,&nbsp;Yohann Loriot","doi":"10.1016/j.euo.2025.01.010","DOIUrl":"10.1016/j.euo.2025.01.010","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"8 3","pages":"Page 853"},"PeriodicalIF":8.3,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143363920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Redefining Good-prognosis Seminoma: Implications for Clinical Practice of the Updated International Germ Cell Cancer Collaborative Group Classification and Results from the SEMITrends Survey. 重新定义预后良好的精原细胞瘤:更新的国际生殖细胞癌合作分类的临床实践意义和来自半趋势调查的结果。
IF 8.3 1区 医学
European urology oncology Pub Date : 2025-02-05 DOI: 10.1016/j.euo.2025.01.006
Anna Patrikidou, Christoph Oing, Christos Markellos, Axel Heidenreich, Ricardo Leao, Nicola Nicolai, Joost Boormans, Stefanie Fischer, Christian Fankhauser, Walter Cazzaniga, Patrizia Giannatempo, Daniel Berney, Hendrik Gremmels, Robert Cornes, Florian Janisch, Domenico Di Nardo, Alexandros Papachristofilou, Karim Fizazi, Togrim Tandstad, David Nicol, Robert Huddart
{"title":"Redefining Good-prognosis Seminoma: Implications for Clinical Practice of the Updated International Germ Cell Cancer Collaborative Group Classification and Results from the SEMITrends Survey.","authors":"Anna Patrikidou, Christoph Oing, Christos Markellos, Axel Heidenreich, Ricardo Leao, Nicola Nicolai, Joost Boormans, Stefanie Fischer, Christian Fankhauser, Walter Cazzaniga, Patrizia Giannatempo, Daniel Berney, Hendrik Gremmels, Robert Cornes, Florian Janisch, Domenico Di Nardo, Alexandros Papachristofilou, Karim Fizazi, Togrim Tandstad, David Nicol, Robert Huddart","doi":"10.1016/j.euo.2025.01.006","DOIUrl":"https://doi.org/10.1016/j.euo.2025.01.006","url":null,"abstract":"<p><p>The 2021 updated International Germ Cell Cancer Collaborative Group classification for seminomatous germ cell tumours confirmed and refined the original classification, introducing the notion that lactate dehydrogenase (LDH) elevation above 2.5 times the upper limit of normal separates the good-risk prognostic group into two distinct subgroups, with clearly inferior survival outcomes for the high-LDH subgroup. Validation of this prognostic factor has understandably opened the question of the optimal management for patients with high-LDH good-risk seminoma. In the absence of prospective evidence, guideline-recommended management options have not changed. However, there is evidence from the testicular cancer community that management trends might have been influenced by the poor prognosis associated with elevated LDH. The Testicular Cancer Guidelines Panel of the European Association of Urology has undertaken a global survey among oncologists and onco-urologists to document management trends and differences. PATIENT SUMMARY: Levels of an enzyme called LDH (lactate dehydrogenase) can differ among patients with testicular cancer that has good prognosis. Recent evidence shows worse outcomes for patients with higher LDH. This information should be used to update clinical guidelines and to tailor personalised treatment plans for these patients.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143363928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信